Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-FOXP3 ASO
- Development stage
- Preclinical
- Lead developer
- AUM LifeTech
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
anti-FOXP3 ASO (also known as FOXP3 AUMsilence ASO) is a preclinical-stage self-delivering antisense oligonucleotide (ASO) developed by AUM LifeTech in collaboration with the Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania. It utilizes AUM LifeTech's proprietary FANA (2'-deoxy-2'-fluoro-beta-D-arabinose) RNA silencing technology to selectively target and downregulate FOXP3 (forkhead box P3) mRNA. FOXP3 is a key transcription factor essential for the development and immunosuppressive function of regulatory T cells (Tregs). By silencing FOXP3, the ASO inhibits Treg-mediated immunosuppression within the tumor microenvironment, thereby enhancing anti-tumor immunity. The therapeutic is being developed as a non-viral cancer immunotherapy for the treatment of solid tumors, including lung cancer, mesothelioma, and melanoma.
- Other names
- FOXP3 ASOFOXP-3 ASOFOXP 3 ASOFOXP3 AUMsilence ASOFOXP-3 AUMsilence ASOFOXP 3 AUMsilence ASOanti-FOXP3 FANA ASOanti-FOXP-3 FANA ASOanti-FOXP 3 FANA ASOself-delivering anti-FOXP3 ASO
02
Targets
FOXP3 (Forkhead box protein P3)
Beyond the preview
Go deeper on anti-FOXP3 ASO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-FOXP3 ASO.